1/ Joe Manchin called Biden’s $2 trillion Build Back Better plan “dead.” When asked about the legislation, Manchin replied: “What Build Back Better bill? It’s dead.” Manchin, however, has said he remains open to a smaller bill aimed at reducing carbon emissions, creating free pre-Kindergarten programs, and increasing federal health care subsidies, but that he hasn’t yet taken part in any negotiations with the White House. In December, Manchin abruptly announced his opposition to the 10-year, roughly $2 trillion social and climate spending package, which had already passed the House. (Associated Press / Bloomberg / NBC News)

2/ At least 4 million people quit or changed jobs in December – down from last month’s all-time high but still near record levels. Job openings totaled nearly 10.9 million in December – more than 4.6 million above the total unemployment level. The White House, meanwhile, warned that Friday’s job report data for last month could overstate the number of unemployed people, saying the January surveys were taken at the height of Covid-19 absences stemming from the holidays. (Washington Post / CNBC / Bloomberg / Wall Street Journal)

3/ The U.S. daily death toll from Covid-19 rose to an average of more than 2,400 fatalities over the previous seven days – up 39% over the past two weeks and the highest level since mid-February last year. The last time U.S. Covid-19 deaths were this high, vaccines weren’t yet widely available. (CNBC / Wall Street Journal)

4/ Pfizer asked the FDA to authorize their Covid-19 vaccine for children ages 6 months to 5 years. The FDA had urged Pfizer to apply for emergency use authorization for their two-dose vaccine now so that young children would be eligible for a booster by the time the results from the three-dose trial are available. In a clinical trial, the two-dose regimen, while safe, failed to produce the expected immunity in 2- to 5-year-olds in a clinical trial, although it did so for the babies up to age 2. Federal regulators, however, believe that two doses should provide enough protection against the Omicron variant. Data on a third shot is not expected to be available until at least late March. The FDA will convene a panel of independent researchers and physicians in mid-February to review the data, potentially making the first vaccine for young children by the end of the month. The Pfizer shots contain one-tenth of the dose given to adults. There are more than 19 million Americans under 5 years old. (CNN / NBC News /